{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:55:40Z","timestamp":1787590540964,"version":"build-2736575974"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04887-2","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T05:06:55Z","timestamp":1748668015000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Optimizing statin therapy in HIV-infected patients: a review of pharmacotherapy considerations"],"prefix":"10.1186","volume":"25","author":[{"given":"Ramin","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Khalili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7699-8538","authenticated-orcid":false,"given":"Keyhan","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"issue":"4","key":"4887_CR1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1001\/jamacardio.2023.5661","volume":"9","author":"MT Lu","year":"2024","unstructured":"Lu MT, Ribaudo H, Foldyna B, Zanni MV, Mayrhofer T, Karady J, et al. Effects of pitavastatin on coronary artery disease and inflammatory biomarkers in HIV: mechanistic substudy of the REPRIEVE randomized clinical trial. JAMA cardiology. 2024;9(4):323\u201334.","journal-title":"JAMA cardiology"},{"issue":"13","key":"4887_CR2","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1177\/09564624211029392","volume":"32","author":"MC Mueller","year":"2021","unstructured":"Mueller MC, Usadel S, Kern WV, Zirlik A, Zhou Q. Proportion of patients eligible for statin therapy substantially varies between different cardiovascular disease risk calculators and guidelines used. Int J STD AIDS. 2021;32(13):1188\u201395.","journal-title":"Int J STD AIDS"},{"issue":"4","key":"4887_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3390\/life14040449","volume":"14","author":"E Papantoniou","year":"2024","unstructured":"Papantoniou E, Arvanitakis K, Markakis K, Papadakos SP, Tsachouridou O, Popovic DS, et al. Pathophysiology and clinical management of dyslipidemia in people living with HIV: sailing through rough seas. Life. 2024;14(4):449.","journal-title":"Life"},{"issue":"8","key":"4887_CR4","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to prevent cardiovascular disease in HIV infection. N Engl J Med. 2023;389(8):687\u201399.","journal-title":"N Engl J Med"},{"issue":"5","key":"4887_CR5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1097\/COH.0000000000000752","volume":"17","author":"KV Fitch","year":"2022","unstructured":"Fitch KV, Fulda ES, Grinspoon SK. Statins for primary cardiovascular disease prevention among people with HIV: emergent directions. Curr Opin HIV AIDS. 2022;17(5):293\u2013300.","journal-title":"Curr Opin HIV AIDS"},{"key":"4887_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.12688\/f1000research.28262.1","volume":"10","author":"E Yunihastuti","year":"2021","unstructured":"Yunihastuti E, Rusdi L, Azizi MS, Estiasari R, Jasirwan COM, Wulandari EAT, et al. Effect of atorvastatin on subclinical atherosclerosis in virally-suppressed HIV-infected patients with CMV seropositivity: a randomized double-blind placebo-controlled trial. F1000Res. 2021;10:151.","journal-title":"F1000Res."},{"issue":"20","key":"4887_CR7","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1016\/j.jacc.2020.03.025","volume":"75","author":"F Boccara","year":"2020","unstructured":"Boccara F, Kumar PN, Caramelli B, Calmy A, L\u00f3pez JAG, Bray S, et al. Evolocumab in HIV-infected patients with dyslipidemia: primary results of the randomized, double-blind BEIJERINCK study. J Am Coll Cardiol. 2020;75(20):2570\u201384.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"4887_CR8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1097\/QAD.0000000000002769","volume":"35","author":"DC Boettiger","year":"2021","unstructured":"Boettiger DC, Kerr S, Chattranukulchai P, Siwamogsatham S, Avihingsanon A. Maintenance of statin therapy among people living with HIV. AIDS. 2021;35(4):567\u201374.","journal-title":"AIDS"},{"issue":"2","key":"4887_CR9","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1161\/CIR.0000000000000695","volume":"140","author":"MJ Feinstein","year":"2019","unstructured":"Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019;140(2):e98\u2013124.","journal-title":"Circulation"},{"issue":"8","key":"4887_CR10","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/infdis\/jir507","volume":"204","author":"MM Lederman","year":"2011","unstructured":"Lederman MM, Calabrese L, Funderburg NT, Clagett B, Medvik K, Bonilla H, et al. Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. J Infect Dis. 2011;204(8):1217\u201326.","journal-title":"J Infect Dis."},{"issue":"12","key":"4887_CR11","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1086\/652749","volume":"201","author":"J Neuhaus","year":"2010","unstructured":"Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788\u201395.","journal-title":"J Infect Dis"},{"issue":"4","key":"4887_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.immuni.2013.10.001","volume":"39","author":"SG Deeks","year":"2013","unstructured":"Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013;39(4):633\u201345.","journal-title":"Immunity"},{"issue":"2","key":"4887_CR13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/cid\/ciw683","volume":"64","author":"I Sereti","year":"2017","unstructured":"Sereti I, Krebs SJ, Phanuphak N, Fletcher JL, Slike B, Pinyakorn S, et al. Editor\u2019s choice: persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection. Clin Infect Dis. 2017;64(2):124.","journal-title":"Clin Infect Dis"},{"key":"4887_CR14","doi-asserted-by":"publisher","first-page":"1339338","DOI":"10.3389\/fimmu.2024.1339338","volume":"15","author":"V Mehraj","year":"2024","unstructured":"Mehraj V, Chen J, Routy J-P. Effects of statins beyond lipid-lowering agents in ART-treated HIV infection. Front Immunol. 2024;15:1339338.","journal-title":"Front Immunol"},{"issue":"10","key":"4887_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/ofid\/ofaa425","volume":"7","author":"TM Temu","year":"2020","unstructured":"Temu TM, Polyak SJ, Zifodya JS, Wanjalla CN, Koethe JR, Masyuko S, et al. Endothelial dysfunction is related to monocyte activation in antiretroviral-treated people with HIV and HIV-negative adults in Kenya. Open Forum Infect Dis.\u00a0Oxford University Press US. 2020;7(10):425.","journal-title":"Open Forum Infect Dis."},{"issue":"6","key":"4887_CR16","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1016\/j.clinthera.2024.04.011","volume":"46","author":"TF Mafumhe","year":"2024","unstructured":"Mafumhe TF, Regalado G, Olojede SO, Lawal SK, Azu OO. Comparison of switching between antiretroviral agents versus introducing lipid-lowering agents for HAART-induced dyslipidemia. Clin Ther. 2024;46(6):e114\u201324.","journal-title":"Clin Ther."},{"issue":"4","key":"4887_CR17","first-page":"449","volume":"14","author":"E Papantoniou","year":"2024","unstructured":"Papantoniou E, Arvanitakis K, Markakis K, Papadakos SP, Tsachouridou O, Popovic DS, et al. Pathophysiology and clinical management of dyslipidemia in people living with HIV: sailing through rough seas. Life (Basel, Switzerland). 2024;14(4):449.","journal-title":"Life (Basel, Switzerland)."},{"issue":"9","key":"4887_CR18","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.3390\/ijerph20095668","volume":"20","author":"K Mokgalaboni","year":"2023","unstructured":"Mokgalaboni K, Phoswa WN, Yates S, Lebelo SL, Madiba S, Modjadji P. A systematic review and meta-analysis on the impact of statin treatment in HIV patients on antiretroviral therapy. Int J Environ Res Public Health. 2023;20(9):5668.","journal-title":"Int J Environ Res Public Health"},{"key":"4887_CR19","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ."},{"issue":"5","key":"4887_CR20","doi-asserted-by":"publisher","first-page":"e207","DOI":"10.1016\/j.chest.2022.07.025","volume":"162","author":"JD Douketis","year":"2022","unstructured":"Douketis JD, Spyropoulos AC, Murad MH, Arcelus JI, Dager WE, Dunn AS, et al. Perioperative management of antithrombotic therapy: an American college of chest physicians clinical practice guideline. Chest. 2022;162(5):e207\u201343.","journal-title":"Chest"},{"key":"4887_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.phrs.2014.03.002","volume":"88","author":"CR Sirtori","year":"2014","unstructured":"Sirtori CR. The pharmacology of statins. Pharmacol Res. 2014;88:3\u201311.","journal-title":"Pharmacol Res"},{"issue":"2","key":"4887_CR22","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/v16020278","volume":"16","author":"F Wu","year":"2024","unstructured":"Wu F, Wang C, Li S, Ye Y, Cui M, Liu Y, et al. Association between statins administration and influenza susceptibility: a systematic review and meta-analysis of longitudinal studies. Viruses. 2024;16(2):278.","journal-title":"Viruses"},{"issue":"2","key":"4887_CR23","first-page":"e27","volume":"82","author":"RJ Bedimo","year":"2019","unstructured":"Bedimo RJ, Mar H, Bosch RJ, Drechsler H, Cyktor JC, Macatangay BJ, et al. Brief report: no evidence for an association between statin use and lower biomarkers of HIV persistence or immune activation\/inflammation during effective ART. JAIDS. 2019;82(2):e27\u201331.","journal-title":"JAIDS"},{"issue":"2","key":"4887_CR24","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","volume":"92","author":"PH Jones","year":"2003","unstructured":"Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152\u201360.","journal-title":"Am J Cardiol"},{"issue":"6","key":"4887_CR25","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1194\/jlr.P002816","volume":"51","author":"PJ Barter","year":"2010","unstructured":"Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. J Lipid Res. 2010;51(6):1546\u201353.","journal-title":"J Lipid Res"},{"issue":"25","key":"4887_CR26","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082\u2013143.","journal-title":"Circulation"},{"issue":"7","key":"4887_CR27","first-page":"167","volume":"11","author":"Z Althanoon","year":"2020","unstructured":"Althanoon Z, Faisal IM, Ahmad AA, Merkhan MM, Merkhan MM. Pharmacological aspects of statins are relevant to their structural and physicochemical properties. Syst Rev Pharm. 2020;11(7):167\u201371.","journal-title":"Syst Rev Pharm"},{"issue":"1","key":"4887_CR28","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","volume":"19","author":"M Schachter","year":"2005","unstructured":"Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117\u201325.","journal-title":"Fundam Clin Pharmacol"},{"issue":"10","key":"4887_CR29","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00228-002-0541-7","volume":"58","author":"SG Simonson","year":"2003","unstructured":"Simonson SG, Martin PD, Mitchell P, Schneck DW, Lasseter KC, Warwick MJ. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment. Eur J Clin Pharmacol. 2003;58(10):669\u201375.","journal-title":"Eur J Clin Pharmacol"},{"issue":"21","key":"4887_CR30","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","volume":"134","author":"BS Wiggins","year":"2016","unstructured":"Wiggins BS, Saseen JJ, Page RL 2nd, Reed BN, Sneed K, Kostis JB, et al. Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2016;134(21):e468\u201395.","journal-title":"Circulation"},{"issue":"3","key":"4887_CR31","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2165\/11319380-000000000-00000","volume":"33","author":"YS Chatzizisis","year":"2010","unstructured":"Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33(3):171\u201387.","journal-title":"Drug Saf"},{"issue":"4","key":"4887_CR32","first-page":"455","volume":"86","author":"M Abdo","year":"2021","unstructured":"Abdo M, Langan SJ, MaWhinney S, Sun J, Lake JE, Palella FJ, et al. Effect of statin therapy on age-associated changes in physical function among men with and without HIV in the multicenter AIDS cohort study. JAIDS. 2021;86(4):455\u201362.","journal-title":"JAIDS"},{"issue":"2","key":"4887_CR33","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/QAD.0000000000002748","volume":"35","author":"RJ Bedimo","year":"2021","unstructured":"Bedimo RJ, Park LS, Shebl FM, Sigel K, Rentsch CT, Crothers K, et al. Statin exposure and risk of cancer in people with and without HIV infection. AIDS. 2021;35(2):325\u201334.","journal-title":"AIDS"},{"issue":"6","key":"4887_CR34","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s11904-023-00669-7","volume":"20","author":"K Wegermann","year":"2023","unstructured":"Wegermann K, Moylan C, Naggie S. Fatty liver disease: enter the metabolic era. Curr HIV\/AIDS Rep. 2023;20(6):405\u201318.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"6","key":"4887_CR35","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1007\/s11904-023-00677-7","volume":"20","author":"R Rohani","year":"2023","unstructured":"Rohani R, Malakismail J, Njoku E. Pharmacological and behavioral interventions to mitigate premature aging in patients with HIV. Curr HIV\/AIDS Rep. 2023;20(6):394\u2013404.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"2","key":"4887_CR36","first-page":"202","volume":"82","author":"SB Ascher","year":"2019","unstructured":"Ascher SB, Scherzer R, Nishtala A, Jotwani V, Grunfeld C, Parikh CR, et al. Association of statin use with kidney damage and function among HIV-infected men. JAIDS. 2019;82(2):202\u201310.","journal-title":"JAIDS"},{"issue":"6","key":"4887_CR37","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1093\/infdis\/jiaa196","volume":"222","author":"C Defilippi","year":"2020","unstructured":"Defilippi C, Toribio M, Wong LP, Sadreyev R, Grundberg I, Fitch KV, et al. Differential plasma protein regulation and statin effects in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients utilizing a proteomics approach. J Infect Dis. 2020;222(6):929\u201339.","journal-title":"J Infect Dis"},{"issue":"2","key":"4887_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.20411\/pai.v6i2.461","volume":"6","author":"A Yadav","year":"2021","unstructured":"Yadav A, Kossenkov AV, Showe LC, Ratcliffe SJ, Choi GH, Montaner LJ, et al. Lack of atorvastatin effect on monocyte gene expression and inflammatory markers in HIV-1-infected ART-suppressed individuals at risk of non-AIDS comorbidities. Pathogens and Immunity. 2021;6(2):1.","journal-title":"Pathogens and Immunity"},{"issue":"9","key":"4887_CR39","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1161\/CIRCRESAHA.119.315082","volume":"125","author":"S Chelvanambi","year":"2019","unstructured":"Chelvanambi S, Gupta SK, Chen X, Ellis BW, Maier BF, Colbert TM, et al. HIV-Nef protein transfer to endothelial cells requires Rac1 activation and leads to endothelial dysfunction implications for statin treatment in HIV patients. Circ Res. 2019;125(9):805\u201320.","journal-title":"Circ Res"},{"issue":"3","key":"4887_CR40","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/COH.0000000000000681","volume":"16","author":"MS Durstenfeld","year":"2021","unstructured":"Durstenfeld MS, Hsue PY. Mechanisms and primary prevention of atherosclerotic cardiovascular disease among people living with HIV. Curr Opin HIV AIDS. 2021;16(3):177\u201385.","journal-title":"Curr Opin HIV AIDS"},{"issue":"9","key":"4887_CR41","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1517\/17425255.2015.1056149","volume":"11","author":"T Hirota","year":"2015","unstructured":"Hirota T, Ieiri I. Drug\u2013drug interactions that interfere with statin metabolism. Expert Opin Drug Metab Toxicol. 2015;11(9):1435\u201347.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"4887_CR42","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/jac\/dkaa099","volume":"75","author":"P Courlet","year":"2020","unstructured":"Courlet P, Livio F, Alves Saldanha S, Scherrer A, Battegay M, Cavassini M, et al. Real-life management of drug\u2013drug interactions between antiretrovirals and statins. J Antimicrob Chemother. 2020;75(7):1972\u201380.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"4887_CR43","first-page":"469","volume":"91","author":"SB Coburn","year":"2022","unstructured":"Coburn SB, Lang R, Zhang J, Palella FJ, Horberg MA, Castillo-Mancilla J, et al. Statins utilization in adults with HIV: the treatment gap and predictors of statin initiation. JAIDS. 2022;91(5):469\u201378.","journal-title":"JAIDS"},{"issue":"2","key":"4887_CR44","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jcct.2019.08.011","volume":"14","author":"B Foldyna","year":"2020","unstructured":"Foldyna B, Lo J, Mayrhofer T, Grinspoon SK, Hoffmann U, Lu MT. Individual coronary plaque changes on serial CT angiography: within-patient heterogeneity, natural history, and statin effects in HIV. J Cardiovasc Comput Tomogr. 2020;14(2):144\u20138.","journal-title":"J Cardiovasc Comput Tomogr"},{"issue":"1","key":"4887_CR45","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jmii.2024.01.003","volume":"57","author":"P-Y Wu","year":"2024","unstructured":"Wu P-Y, Sun H-Y, Huang Y-S, Liu W-D, Lin K-Y, Luo Y-Z, et al. Under-utilization of statins among people with HIV who were aged 40 years or older. J Microbiol Immunol Infect. 2024;57(1):200\u20133.","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"4887_CR46","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12875-024-02370-z","volume":"25","author":"A Ogunbajo","year":"2024","unstructured":"Ogunbajo A, Todd I, Zajdman D, Anderson A, Wali S, Diamant A, et al. Statin use for cardiovascular disease prevention: perceptions among people living with HIV in the United States. BMC primary care. 2024;25(1):116.","journal-title":"BMC primary care"},{"issue":"4","key":"4887_CR47","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/QAI.0000000000003141","volume":"92","author":"MC Cottino","year":"2023","unstructured":"Cottino MC, Kulig CE, Suh JS, Jimenez HR. Evaluation of Statin Prescribing Practices and Predictors of Statin Underutilization in Persons With HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2023;92(4):334\u20139.","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"4887_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12875-021-01563-0","volume":"22","author":"AJ Ober","year":"2021","unstructured":"Ober AJ, Takada S, Zajdman D, Todd I, Horwich T, Anderson A, et al. Factors affecting statin uptake among people living with HIV: primary care provider perspectives. BMC Fam Pract. 2021;22:1\u201313.","journal-title":"BMC Fam Pract"},{"key":"4887_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP171764.APPGL","volume":"23","author":"PS Jellinger","year":"2017","unstructured":"Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017;23:1\u201387.","journal-title":"Endocr Pract"},{"key":"4887_CR50","first-page":"13","volume":"7","author":"VG Athyros","year":"2016","unstructured":"Athyros VG, Sfikas G, Boutari C, Imprialos K, Tziomalos K, Karagiannis A. 2013 American College of Cardiology\/American Heart Association Lipid Guidelines after the 2016 American College of Cardiology Expert Panel Consensus Statement: To err is human; to admit it, divine. Hell J Atheroscler. 2016;7:13\u201326.","journal-title":"Hell J Atheroscler"},{"issue":"4","key":"4887_CR51","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1177\/08971900211000700","volume":"35","author":"AE \u00d6zdener-Poyraz","year":"2022","unstructured":"\u00d6zdener-Poyraz AE, Vaidean G. Preventive Cardiovascular Care in Patients With HIV Infection in an Outpatient Clinic. J Pharm Pract. 2022;35(4):612\u20136.","journal-title":"J Pharm Pract"},{"issue":"4","key":"4887_CR52","doi-asserted-by":"publisher","first-page":"e0232636","DOI":"10.1371\/journal.pone.0232636","volume":"15","author":"BAP Phan","year":"2020","unstructured":"Phan BAP, Ma Y, Scherzer R, Deeks SG, Hsue PY. Association between statin use, atherosclerosis, and mortality in HIV-infected adults. PLoS ONE. 2020;15(4):e0232636.","journal-title":"PLoS ONE"},{"issue":"10","key":"4887_CR53","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/hiv.13150","volume":"22","author":"KJ Pincus","year":"2021","unstructured":"Pincus KJ, Blackman AL, Suen SY, Devabhakthuni S, Gale S, Noel ZR, et al. Statin gap in patients living with HIV: assessing dose appropriateness. HIV Med. 2021;22(10):917\u201323.","journal-title":"HIV Med"},{"issue":"12","key":"4887_CR54","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1007\/s40265-024-02105-5","volume":"84","author":"M Banach","year":"2024","unstructured":"Banach M, Reiner \u017d, Surma S, Bajraktari G, Bielecka-Dabrowa A, Bunc M, et al. 2024 Recommendations on the Optimal Use of Lipid-Lowering Therapy in Established Atherosclerotic Cardiovascular Disease and Following Acute Coronary Syndromes: A Position Paper of the International Lipid Expert Panel (ILEP). Drugs. 2024;84(12):1541\u201377.","journal-title":"Drugs"},{"issue":"8","key":"4887_CR55","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","volume":"389","author":"SK Grinspoon","year":"2023","unstructured":"Grinspoon SK, Fitch KV, Zanni MV, Fichtenbaum CJ, Umbleja T, Aberg JA, et al. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. N Engl J Med. 2023;389(8):687\u201399.","journal-title":"N Engl J Med"},{"issue":"3","key":"4887_CR56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1177\/17151635231164989","volume":"156","author":"HE Babadagli","year":"2023","unstructured":"Babadagli HE, Barry AR, Thanassoulis G, Pearson GJ. Updated guidelines for the management of dyslipidemia and the prevention of cardiovascular disease in adults by pharmacists. Can Pharm J. 2023;156(3):117\u201327.","journal-title":"Can Pharm J."},{"issue":"6","key":"4887_CR57","first-page":"S58","volume":"71","author":"C Malvestutto","year":"2022","unstructured":"Malvestutto C. The Evolving Landscape of ASCVD Risk Among Patients With HIV. J Fam Pract. 2022;71(6):S58\u201362.","journal-title":"J Fam Pract."},{"issue":"4","key":"4887_CR58","doi-asserted-by":"publisher","first-page":"447","DOI":"10.2217\/clp.11.25","volume":"6","author":"CD Malvestutto","year":"2011","unstructured":"Malvestutto CD, Aberg JA. Management of dyslipidemia in HIV-infected patients. Clin Lipidol. 2011;6(4):447.","journal-title":"Clin Lipidol"},{"issue":"12","key":"4887_CR59","doi-asserted-by":"publisher","first-page":"e0244675","DOI":"10.1371\/journal.pone.0244675","volume":"15","author":"A Pawlos","year":"2020","unstructured":"Pawlos A, Broncel M, Wlaz\u0142owska E, Jab\u0142onowska E, Gorzelak-Pabi\u015b P. Cardiovascular risk and response to lipid lowering therapy in patients with HIV infection according to different recommendations. PLoS ONE. 2020;15(12):e0244675.","journal-title":"PLoS ONE"},{"issue":"28","key":"4887_CR60","doi-asserted-by":"publisher","first-page":"e26631","DOI":"10.1097\/MD.0000000000026631","volume":"100","author":"F Pyarali","year":"2021","unstructured":"Pyarali F, Iordanov R, Ebner B, Grant J, Vincent L, Toirac A, et al. Cardiovascular disease and prevention among people living with HIV in South Florida. Medicine. 2021;100(28):e26631.","journal-title":"Medicine"},{"key":"4887_CR61","doi-asserted-by":"publisher","first-page":"204800402110310","DOI":"10.1177\/20480040211031068","volume":"10","author":"JA Nardolillo","year":"2021","unstructured":"Nardolillo JA, Marrs JC, Anderson SL, Hanratty R, Saseen JJ. Retrospective cohort study of statin prescribing for primary prevention among people living with HIV. JRSM Cardiovasc Dis. 2021;10:20480040211031068.","journal-title":"JRSM Cardiovasc Dis"},{"key":"4887_CR62","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s40261-021-01081-y","volume":"41","author":"L Brunet","year":"2021","unstructured":"Brunet L, Mallon P, Fusco JS, Wohlfeiler MB, Prajapati G, Beyer A, et al. Switch from tenofovir disoproxil fumarate to tenofovir alafenamide in people living with HIV: lipid changes and statin underutilization. Clin Drug Investig. 2021;41:955\u201365.","journal-title":"Clin Drug Investig"},{"issue":"33","key":"4887_CR63","first-page":"102175","volume":"2023","author":"M Pan","year":"2018","unstructured":"Pan M, Agovi AM-A, Anikpo IO, Fasanmi EO, Thompson EL, Reeves JM, Effect of, et al. American College of Cardiology\/American Heart Association Guideline Change on Statin Prescription for People Living with HIV. Preventive Medicine Reports. 2018;2023(33):102175.","journal-title":"Preventive Medicine Reports"},{"issue":"22","key":"4887_CR64","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1093\/ajhp\/zxac224","volume":"79","author":"K Gallegos Aragon","year":"2022","unstructured":"Gallegos Aragon K, Ray G, Conklin J, Stever E, Marquez C, Magallanes A, et al. Underprescribing of statin therapy in people with HIV at risk for atherosclerotic cardiovascular disease. Am J Health Syst Pharm. 2022;79(22):2026\u201331.","journal-title":"Am J Health Syst Pharm"},{"issue":"4","key":"4887_CR65","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1177\/0897190021999790","volume":"35","author":"RP Emmons","year":"2022","unstructured":"Emmons RP, Hastain NV, Miano TA, Schafer JJ. Patients living with HIV are less likely to receive appropriate statin therapy for cardiovascular disease risk reduction. J Pharm Pract. 2022;35(4):568\u201372.","journal-title":"J Pharm Pract"},{"issue":"3","key":"4887_CR66","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/hiv.13195","volume":"23","author":"D Larson","year":"2022","unstructured":"Larson D, Won SH, Ganesan A, Maves RC, Kronmann K, Okulicz JF, et al. Statin usage and cardiovascular risk among people living with HIV in the US Military HIV Natural History Study. HIV Med. 2022;23(3):249\u201358.","journal-title":"HIV Med"},{"key":"4887_CR67","unstructured":"Donald EM. Closing the mortality gap for people living with hiv: updated recommendations for statins for primary prevention of ASCVD. Cardiology Magazine. 2024 2024."},{"issue":"5","key":"4887_CR68","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1089\/aid.2020.0127","volume":"37","author":"SK Hussain","year":"2021","unstructured":"Hussain SK, Golozar A, Widney DP, Rappocciolo G, Penugonda S, Bream JH, et al. Effect of statin use on inflammation and immune activation biomarkers in HIV-infected persons on effective antiretroviral therapy. AIDS Res Hum Retroviruses. 2021;37(5):357\u201367.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"8","key":"4887_CR69","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/cid\/ciu523","volume":"59","author":"Longenecker CT, Hileman CO, Funderburg NT, McComsey GA","year":"2014","unstructured":"Longenecker CT, Hileman CO, Funderburg NT, McComsey GA. Rosuvastatin preserves renal function and lowers cystatin C in HIV-infected subjects on antiretroviral therapy: the SATURN-HIV trial. Clin Infect Dis. 2014;59(8):1148\u201356.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"4887_CR70","first-page":"396","volume":"68","author":"Y Jiang","year":"2015","unstructured":"Funderburg NT, Jiang Y, Debanne SM, Labbato D, Juchnowski S, Ferrari B, et al. Rosuvastatin reduces vascular inflammation and T-cell and monocyte activation in HIV-infected subjects on antiretroviral therapy. JAIDS. 2015;68(4):396\u2013404.","journal-title":"JAIDS"},{"issue":"19","key":"4887_CR71","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/01.CIR.0000100688.17280.E6","volume":"108","author":"PM Ridker","year":"2003","unstructured":"Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation. 2003;108(19):2292\u20137.","journal-title":"Circulation"},{"issue":"9670","key":"4887_CR72","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","volume":"373","author":"PM Ridker","year":"2009","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. The Lancet. 2009;373(9670):1175\u201382.","journal-title":"The Lancet"},{"issue":"1","key":"4887_CR73","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1161\/CIRCULATIONAHA.109.874834","volume":"121","author":"BM Everett","year":"2010","unstructured":"Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. 2010;121(1):143\u201350.","journal-title":"Circulation"},{"issue":"21","key":"4887_CR74","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207.","journal-title":"N Engl J Med"},{"issue":"12","key":"4887_CR75","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1097\/QAD.0000000000003656","volume":"37","author":"HA Mystakelis","year":"2023","unstructured":"Mystakelis HA, Wilson E, Laidlaw E, Poole A, Krishnan S, Rupert A, et al. An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV. AIDS. 2023;37(12):1827\u201335.","journal-title":"AIDS"},{"issue":"1","key":"4887_CR76","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12981-023-00506-2","volume":"20","author":"S Srichatrapimuk","year":"2023","unstructured":"Srichatrapimuk S, Wongsa A, Sungkanuparph S, Kiertiburanakul S, Tassaneetrithep B, Phuphuakrat A. Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study. AIDS Res Ther. 2023;20(1):13.","journal-title":"AIDS Res Ther"},{"key":"4887_CR77","doi-asserted-by":"publisher","first-page":"769740","DOI":"10.3389\/fmed.2021.769740","volume":"8","author":"Y Li","year":"2021","unstructured":"Li Y, Wang Z, Xia H, Zhang J. Influence of statin therapy on the incidence of cardiovascular events, cancer, and all-cause mortality in people living with HIV: A meta-analysis. Front Med. 2021;8:769740.","journal-title":"Front Med"},{"issue":"1","key":"4887_CR78","doi-asserted-by":"publisher","first-page":"18121","DOI":"10.1038\/s41598-022-23102-2","volume":"12","author":"NN Vigny","year":"2022","unstructured":"Vigny NN, Bonsu KO, Kadirvelu A. Effectiveness and safety of statins on outcomes in patients with HIV infection: a systematic review and meta-analysis. Sci Rep. 2022;12(1):18121.","journal-title":"Sci Rep"},{"key":"4887_CR79","doi-asserted-by":"crossref","unstructured":"Lipinski J, Margevicius S, Schluchter MD, Wilson DL, McComsey GA, Longenecker CT. Statin effect on coronary calcium distribution, mass and volume scores and associations with immune activation among HIV+ Persons on antiretroviral therapy. SAGE Publications Sage UK: London, England; 2020.","DOI":"10.3851\/IMP3389"},{"issue":"2","key":"4887_CR80","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2352-3018(14)00032-0","volume":"2","author":"J Lo","year":"2015","unstructured":"Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. The lancet HIV. 2015;2(2):e52\u201363.","journal-title":"The lancet HIV"},{"issue":"4","key":"4887_CR81","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/QAD.0000000000002764","volume":"35","author":"JM Trevillyan","year":"2021","unstructured":"Trevillyan JM, Dart A, Paul E, Cavassini M, Fehr J, Staehelin C, et al. Impact of rosuvastatin on atherosclerosis in people with HIV at moderate cardiovascular risk: a randomised, controlled trial. AIDS. 2021;35(4):619\u201324.","journal-title":"AIDS"},{"issue":"4","key":"4887_CR82","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1093\/infdis\/jiaa775","volume":"224","author":"AC Hearps","year":"2021","unstructured":"Hearps AC, Angelovich TA, Trevillyan JM, Wong ME, Calmy A, Hoy JF, et al. Effect of rosuvastatin therapy on biomarkers of inflammation and immune activation in people with human immunodeficiency virus at intermediate cardiovascular risk. J Infect Dis. 2021;224(4):667\u201372.","journal-title":"J Infect Dis"},{"issue":"9","key":"4887_CR83","doi-asserted-by":"publisher","first-page":"e0238575","DOI":"10.1371\/journal.pone.0238575","volume":"15","author":"E Negredo","year":"2020","unstructured":"Negredo E, Jim\u00e9nez M, Puig J, Loste C, P\u00e9rez-\u00c1lvarez N, Urrea V, et al. A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. PLoS ONE. 2020;15(9):e0238575.","journal-title":"PLoS ONE"},{"key":"4887_CR84","doi-asserted-by":"publisher","first-page":"e25494","DOI":"10.1002\/jia2.25494","volume":"23","author":"DC Boettiger","year":"2020","unstructured":"Boettiger DC, Newall AT, Chattranukulchai P, Chaiwarith R, Khusuwan S, Avihingsanon A, et al. Statins for atherosclerotic cardiovascular disease prevention in people living with HIV in Thailand: a cost-effectiveness analysis. J Int AIDS Soc. 2020;23:e25494.","journal-title":"J Int AIDS Soc"},{"issue":"7","key":"4887_CR85","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/17512433.2024.2344672","volume":"17","author":"SSM Alla","year":"2024","unstructured":"Alla SSM, Shah DJ, Ratheesh V, Alla D, Tummala T, Khetan MS, et al. Effectiveness of statins in people living with HIV: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol. 2024;17(7):615\u201323.","journal-title":"Expert Rev Clin Pharmacol."},{"issue":"11","key":"4887_CR86","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/aid.2020.0273","volume":"37","author":"AA Ashuro","year":"2021","unstructured":"Ashuro AA, Fan Y-G, Fu Y-S, Di D-S, Sam NB, Pan H-F, et al. The effect of rosuvastatin on plasma\/serum levels of high-sensitivity C-reactive protein, interleukin-6, and D-dimer in people living with human immunodeficiency virus: a systematic review and meta-analysis. AIDS Res Hum Retroviruses. 2021;37(11):821\u201333.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"4887_CR87","doi-asserted-by":"publisher","first-page":"e0256926","DOI":"10.1371\/journal.pone.0256926","volume":"16","author":"DC Boettiger","year":"2021","unstructured":"Boettiger DC, Chattranukulchai P, Avihingsanon A, Chaiwarith R, Khusuwan S, Law MG, et al. Atherosclerotic cardiovascular disease thresholds for statin initiation among people living with HIV in Thailand: A cost-effectiveness analysis. PLoS ONE. 2021;16(9):e0256926.","journal-title":"PLoS ONE"},{"issue":"1","key":"4887_CR88","first-page":"27","volume":"25","author":"S Marin","year":"2023","unstructured":"Marin S, Qui\u00f1ones C, Jim\u00e9nez CC, Valls E, Terricabras E, Estrada L, et al. The management of polypharmacy in people living with HIV. AIDS Rev. 2023;25(1):27\u201340.","journal-title":"AIDS Rev."},{"issue":"5","key":"4887_CR89","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/14656566.2020.1714028","volume":"21","author":"L Strilchuk","year":"2020","unstructured":"Strilchuk L, Tocci G, Fogacci F, Cicero AF. An overview of rosuvastatin\/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia. Expert Opin Pharmacother. 2020;21(5):531\u20139.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"4887_CR90","doi-asserted-by":"publisher","first-page":"260","DOI":"10.15386\/mpr-2305","volume":"95","author":"HAH Al Sayed","year":"2022","unstructured":"Al Sayed HAH, Sharif-Askari NS, Rahimi MR. Clinically significant drug interactions between antiretroviral and co-prescribed drugs in HIV infected patients: retrospective cohort study. Medicine and Pharmacy Reports. 2022;95(3):260.","journal-title":"Medicine and Pharmacy Reports"},{"issue":"4","key":"4887_CR91","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1089\/aid.2020.0263","volume":"37","author":"LD York","year":"2021","unstructured":"York LD, Fisher JM, Malladi L, August JA, Ellis KE, Marquez JL, et al. Antiretroviral Laboratory Monitoring and Implications for HIV Clinical Care in the Era of COVID-19 and Beyond. AIDS Res Hum Retroviruses. 2021;37(4):297\u2013303.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"4887_CR92","doi-asserted-by":"publisher","first-page":"2021-8-7","DOI":"10.7573\/dic.2021-8-7","volume":"11","author":"D Lee","year":"2022","unstructured":"Lee D. HIV: how to manage dyslipidaemia in HIV. Drugs in Context. 2022;11:2021-8\u20137.","journal-title":"Drugs in Context."},{"issue":"2","key":"4887_CR93","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/hiv.12984","volume":"22","author":"L Gazzola","year":"2021","unstructured":"Gazzola L, Tagliaferri G, De Bona A, Mondatore D, Borsino C, Bini T, et al. Dyslipidaemia after switch to tenofovir alafenamide (TAF)-based cART regimens in a cohort of HIV-positive patients: what clinical relevance? HIV Med. 2021;22(2):140\u20135.","journal-title":"HIV Med"},{"issue":"2","key":"4887_CR94","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/CRD.0000000000000587","volume":"33","author":"S Datla","year":"2023","unstructured":"Datla S, Kumar S. PCSK9 Inhibitors\u2014a new hope for dyslipidemia in HIV. Cardiol Rev. 2023;33(2):112\u20133.","journal-title":"Cardiol Rev."},{"key":"4887_CR95","first-page":"6","volume":"8","author":"DB Chastain","year":"2017","unstructured":"Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. J Clin Transl Endocrinol. 2017;8:6\u201314.","journal-title":"J Clin Transl Endocrinol"},{"issue":"4","key":"4887_CR96","first-page":"449","volume":"14","author":"E Papantoniou","year":"2024","unstructured":"Papantoniou E, Arvanitakis K, Markakis K, Papadakos SP, Tsachouridou O, Popovic DS, et al. From pathophysiology to drug interactions and clinical management of dyslipidemia in people living with HIV: sailing through rough seas. Life (Basel). 2024;14(4):449.","journal-title":"Life (Basel)."},{"key":"4887_CR97","doi-asserted-by":"publisher","first-page":"2021-8-7","DOI":"10.7573\/dic.2021-8-7","volume":"11","author":"D Lee","year":"2022","unstructured":"Lee D. HIV: how to manage dyslipidaemia in HIV. Drugs in context. 2022;11:2021-8\u20137.","journal-title":"Drugs in context."},{"issue":"7","key":"4887_CR98","doi-asserted-by":"publisher","first-page":"e011662","DOI":"10.1161\/JAHA.118.011662","volume":"8","author":"U Laufs","year":"2019","unstructured":"Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019;8(7):e011662.","journal-title":"J Am Heart Assoc"},{"issue":"14","key":"4887_CR99","doi-asserted-by":"publisher","first-page":"e016263","DOI":"10.1161\/JAHA.120.016263","volume":"9","author":"TM Leucker","year":"2020","unstructured":"Leucker TM, Gerstenblith G, Sch\u00e4r M, Brown TT, Jones SR, Afework Y, et al. Evolocumab, a PCSK9-monoclonal antibody, rapidly reverses coronary artery endothelial dysfunction in people living with HIV and people with dyslipidemia. J Am Heart Assoc. 2020;9(14):e016263.","journal-title":"J Am Heart Assoc"},{"issue":"Supplement_1","key":"4887_CR100","doi-asserted-by":"publisher","first-page":"ehae666.2841","DOI":"10.1093\/eurheartj\/ehae666.2841","volume":"45","author":"S Datla","year":"2024","unstructured":"Datla S, Ali B, Sattouf Z. PCSK9 inhibitors in HIV patients with dyslipidemia. Eur Heart J. 2024;45(Supplement_1):ehae666.2841.","journal-title":"Eur Heart J."},{"issue":"5","key":"4887_CR101","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1097\/QAD.0000000000003175","volume":"36","author":"F Boccara","year":"2022","unstructured":"Boccara F, Caramelli B, Calmy A, Kumar P, L\u00f3pez JAG, Bray S, et al. Long-term effects of evolocumab in participants with HIV and dyslipidemia: results from the open-label extension period. AIDS. 2022;36(5):675\u201382.","journal-title":"AIDS"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04887-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04887-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04887-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T17:02:01Z","timestamp":1748710921000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04887-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,31]]},"references-count":101,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4887"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04887-2","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,31]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"421"}}